Press Room

Press Clipping / Jul 07, 2017

Hovione keeps a keen focus on developing its talent pool

Irish Examiner, 7 Jul 2017

The trend for school-leavers to prefer to automatically opt for college has resulted in a shortage of skilled workers in certain fields, warns Dr Paul Downing, Hovione general manager.

“The single biggest challenge we have experienced is in the area of skills,” says Mr Downing.

He says it’s believed the low number of skilled workers such as electricians, fitters, quality control analysts, instrument technicians as well as automation technicians, is a result of the fall-off in popularity of traditional Apprenticeship programmes and increased parental pressure on school-leavers to earn a degree. Yet, he points out, the traditional apprenticeship route offers all participants potentially excellent careers.

"We would like to see more emphasis placed by second-level career guidance teachers on the option of apprenticeships in all of the different trades," he said, adding that the issue has become a "significant" problem in recent years. The focus of the Hovione pharmaceutical plant in Cork, at which just under 200 people are employed, is Contract Manufacturing, offering both drug substance and particle engineering capabilities and services.

"Because of the shortage we are having to hire contract resources instead of being able to employ permanent staff members," Dr Downing explained.

"We are trying to source laboratory technicians for example, who have become skilled through an Apprenticeship route rather than through a third level degree but it is difficult to find such personnel.

 

Read the full article

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026